You are here

Article Text

Article menu
XML
Guidelines
Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs)
  1. John K Ramage1,
  2. A Ahmed2,
  3. J Ardill3,
  4. N Bax4,
  5. D J Breen5,
  6. M E Caplin6,
  7. P Corrie7,
  8. J Davar8,
  9. A H Davies9,
  10. V Lewington10,
  11. T Meyer11,
  12. J Newell-Price12,
  13. G Poston13,
  14. N Reed14,
  15. A Rockall15,
  16. W Steward16,
  17. R V Thakker17,
  18. C Toubanakis18,
  19. J Valle19,
  20. C Verbeke20,
  21. A B Grossman17
  1. 1Basingstoke and North Hampshire Hospital, Basingstoke, UK
  2. 2Department of Gastroenterology, County Durham and Darlington Foundation Trust, Darlington, UK
  3. 3Peptide Laboratory, Royal Victoria Hospital, Belfast, UK
  4. 4Department of Clinical Pharmacology, University of Sheffield, Sheffield, UK
  5. 5Department of Radiology, Southampton General Hospital, Southampton, UK
  6. 6Department of Gastroenterology, University College London, London, UK
  7. 7Department of Oncology, Addenbrookes Hospital, Cambridge University Hospitals NHS Foundation Trust, Cambridge, UK
  8. 8Department of Cardiology, Royal Free Hospital, London, UK
  9. 9Department of Gastroenterology, University Hospitals of Morecambe Bay Foundation Trust, Barrow-in-Furness, UK
  10. 10Nuclear Medicine, Kings College London, London, UK
  11. 11Department of Oncology, University College London, London, UK
  12. 12Department of Endocrinology, University of Sheffield, Sheffield, UK
  13. 13Department of Surgery, University of Liverpool, Liverpool, UK
  14. 14Department of Oncology, Beatson Centre, Glasgow, UK
  15. 15Department of Radiology, Queen Mary's University, London, UK
  16. 16Department of Oncology, University of Leicester, Leicester, UK
  17. 17Academic Department of Endocrinology, Diabetes and Metabolism, Oxford University, Oxford, UK
  18. 18Department of Gastroenterology, Royal Free Hospital, London, UK
  19. 19Department of Medical Oncology, The Christie Hospital NHS Foundation Trust, Manchester, UK
  20. 20Department of Histopathology, St James's University Hospital, Leeds, UK
  1. Correspondence to Dr John K Ramage, Basingstoke and North Hampshire Hospital, Aldermaston Road, Basingstoke RG24 9NA, UK; john.ramage{at}bnhft.nhs.uk

Abstract

These guidelines update previous guidance published in 2005. They have been revised by a group who are members of the UK and Ireland Neuroendocrine Tumour Society with endorsement from the clinical committees of the British Society of Gastroenterology, the Society for Endocrinology, the Association of Surgeons of Great Britain and Ireland (and its Surgical Specialty Associations), the British Society of Gastrointestinal and Abdominal Radiology and others. The authorship represents leaders of the various groups in the UK and Ireland Neuroendocrine Tumour Society, but a large amount of work has been carried out by other specialists, many of whom attended a guidelines conference in May 2009. We have attempted to represent this work in the acknowledgements section. Over the past few years, there have been advances in the management of neuroendocrine tumours, which have included clearer characterisation, more specific and therapeutically relevant diagnosis, and improved treatments. However, there remain few randomised trials in the field and the disease is uncommon, hence all evidence must be considered weak in comparison with other more common cancers.

  • Clinical decision-making
  • decision analysis
  • intestinal obstruction
  • neuroendocrine cells
  • endocrine tumours
  • neuroendocrine tumours
  • diarrhoea
  • infective colitis
  • salmonella
  • sepsis
  • cancer
  • pancreatic cancer
  • pancreatic endocrine tumour
  • pancreatic tumours
  • peptide receptors
  • gallbladder cancer
  • pancreatitis
  • pancreatic pathology
  • histopathology
  • bilary duct carcinoma

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license. See: http://creativecommons.org/licenses/by-nc/2.0/ and http://creativecommons.org/licenses/by-nc/2.0/legalcode.

https://doi.org/10.1136/gutjnl-2011-300831

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Supplementary materials

    Footnotes

    • Funding Novartis Pharmaceuticals UK Ltd and Ipsen UK provided unrestricted educational grants for the original working party meeting. Novartis Pharmaceuticals UK Ltd also provided financial assistance to allow Porterhouse Medical Ltd, a medical writing agency, to aid the drafting of this manuscript.

    • Competing interests JR has received honoraria and educational grants from Ipsen and Novartis; AA has received educational support and research grants from Ipsen and Novartis; JA has received research funding, educational grants and travel grants from Ipsen and Novartis; NB has received educational grants and research funding from Ipsen and Novartis; DB has no conflicts of interest; MC has received honoraria from Novartis, Ipsen, Pfizer and Lexicon for advisory boards or invited lectures, and research/educational grants from Novartis and Ipsen; PC has received honoraria for advisory boards and lectures from Novartis and educational travel support grants from Ipsen; AD has received research funding and travel expenses for meetings from Novartis; VL has received honoraria for advisory boards and educational grants from Novartis and Ipsen; TM has sat on an advisory board for Keocyte and received partial funding from Pfizer for attendance at ENETs in 2010; JD has received educational grants from Novartis and Ipsen; JN-P has received honoraria and undertaken consultancy work from Novartis and Ipsen, research funding from Novartis, and educational grants for attending meetings from Novartis and Ipsen; GP has received honoraria for advisory boards and lectures from Novartis and Ipsen, educational travel support grants from Novartis and Ipsen, and support for clinical personnel (NET CNS) from Novartis; NR has received honoraria for advisory boards from Novartis and Ipsen and a travel grant from Pfizer; AR has received honoraria for an advisory board and educational lectures from Novartis as well as travel support to those events; WS has received educational grants and honoraria from Ipsen and Novartis; RT has received honoraria and lecture fees from Ipsen, support for clinical personnel from the MRC and Wellcome Trust Clinical Training Fellowships, and educational grants from MRC, Wellcome Trust, EU FP6 and EU FP7; CT has received honoraria and educational support from Novartis and educational support from Ipsen; JV has received honoraria from Pfizer and Novartis, funding for clinical personnel from Novartis, an educational grant from Novartis and research funding from Pfizer, Novartis and Ipsen; CV has received educational grants for conference attendance from Ipsen; AG has received honoraria and educational grant support from Novartis and Ipsen.

    • Provenance and peer review Not commissioned; externally peer reviewed.